PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders.
High growth potential and slightly overvalued.
Share Price & News
How has Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: P91's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: P91 exceeded the German Biotechs industry which returned -5.1% over the past year.
Return vs Market: P91 exceeded the German Market which returned -17.5% over the past year.
Price Volatility Vs. Market
How volatile is Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: P91 (€37) is trading below our estimate of fair value (€125.62)
Significantly Below Fair Value: P91 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: P91 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: P91 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate P91's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: P91 is overvalued based on its PB Ratio (4.2x) compared to the DE Biotechs industry average (3.6x).
How is Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: P91 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: P91 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: P91's is expected to become profitable in the next 3 years.
Revenue vs Market: P91's revenue (23.7% per year) is forecast to grow faster than the German market (4.2% per year).
High Growth Revenue: P91's revenue (23.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: P91 is forecast to be unprofitable in 3 years.
How has Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: P91 is currently unprofitable.
Growing Profit Margin: P91 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: P91 is unprofitable, and losses have increased over the past 5 years at a rate of -6.6% per year.
Accelerating Growth: Unable to compare P91's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: P91 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: P91 has a negative Return on Equity (-42.33%), as it is currently unprofitable.
How is Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: P91's short term assets ($779.3M) exceed its short term liabilities ($235.9M).
Long Term Liabilities: P91's short term assets ($779.3M) do not cover its long term liabilities ($793.6M).
Debt to Equity History and Analysis
Debt Level: P91's debt to equity ratio (52.8%) is considered high.
Reducing Debt: Insufficient data to determine if P91's debt to equity ratio has reduced over the past 5 years.
Inventory Level: P91 has a low level of unsold assets or inventory.
Debt Coverage by Assets: P91's debt is covered by short term assets (assets are 2.5x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: P91 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if P91 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate P91's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate P91's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if P91's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if P91's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of P91's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stuart Peltz (59yo)
Dr. Stuart W. Peltz, Ph.D co-founded PTC Therapeutics Inc. in 1998 and has been its Chief Executive Officer since 1998. Dr. Peltz served as the President of PTC Therapeutics Inc. from 1998 to April 2012. P ...
CEO Compensation Analysis
Compensation vs Market: Stuart's total compensation ($USD4.02M) is about average for companies of similar size in the German market ($USD3.71M).
Compensation vs Earnings: Stuart's compensation has increased whilst the company is unprofitable.
|Chief Operating Officer||2.83yrs||US$1.95m||0.065% $1.5m|
|Senior VP of Finance & Chief Accounting Officer||0.83yr||US$1.15m||0.0068% $154.5k|
|Chief Technical Operations Officer||1.17yrs||US$1.61m||0.027% $625.7k|
|Executive VP & Chief Legal Officer||8yrs||US$1.60m||0.047% $1.1m|
|Chief Financial Officer & Treasurer||0.83yr||no data||0.0041% $93.9k|
|Chief Scientific Officer||1.17yrs||no data||no data|
|Investor Relations Officer||no data||no data||no data|
|Vice President of Corporate Communications||no data||no data||no data|
Experienced Management: P91's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
|Chairman of the Board||15.33yrs||US$415.08k||0.15% $3.5m|
|Independent Director||14.25yrs||US$245.54k||no data|
|Member of the Scientific Advisory Board||no data||no data||no data|
|Independent Director||7.5yrs||US$230.54k||no data|
|Independent Director||1.25yrs||US$316.75k||no data|
|Member of Scientific Advisory Board||16.33yrs||no data||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
Experienced Board: P91's board of directors are seasoned and experienced ( 15.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: P91 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.4%.
PTC Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: PTC Therapeutics, Inc.
- Ticker: P91
- Exchange: DB
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.527b
- Listing Market Cap: US$2.279b
- Shares outstanding: 62.63m
- Website: https://www.ptcbio.com
Number of Employees
- PTC Therapeutics, Inc.
- 100 Corporate Court
- South Plainfield
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PTCT||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jun 2013|
|P91||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2013|
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and strategic collaboration agreement with Odylia Therapeutics Inc. to develop gene therapies in rare inherited retinal diseases. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/29 23:12|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.